Impact of mesenchymal stromal cell-derived vesicular cargo on B-cell acute lymphoblastic leukemia progression.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
11 04 2023
Historique:
accepted: 15 08 2022
received: 08 03 2022
medline: 4 4 2023
pubmed: 1 9 2022
entrez: 31 8 2022
Statut: ppublish

Résumé

Leukemia cells reciprocally interact with their surrounding bone marrow microenvironment (BMM), rendering it hospitable to leukemia cell survival, for instance through the release of small extracellular vesicles (sEVs). In contrast, we show here that BMM deficiency of pleckstrin homology domain family M member 1 (PLEKHM1), which serves as a hub between fusion and secretion of intracellular vesicles and is important for vesicular secretion in osteoclasts, accelerates murine BCR-ABL1+ B-cell acute lymphoblastic leukemia (B-ALL) via regulation of the cargo of sEVs released by BMM-derived mesenchymal stromal cells (MSCs). PLEKHM1-deficient MSCs and their sEVs carry increased amounts of syntenin and syndecan-1, resulting in a more immature B-cell phenotype and an increased number/function of leukemia-initiating cells (LICs) via focal adhesion kinase and AKT signaling in B-ALL cells. Ex vivo pretreatment of LICs with sEVs derived from PLEKHM1-deficient MSCs led to a strong trend toward acceleration of murine and human BCR-ABL1+ B-ALL. In turn, inflammatory mediators such as recombinant or B-ALL cell-derived tumor necrosis factor α or interleukin-1β condition murine and human MSCs in vitro, decreasing PLEKHM1, while increasing syntenin and syndecan-1 in MSCs, thereby perpetuating the sEV-associated circuit. Consistently, human trephine biopsies of patients with B-ALL showed a reduced percentage of PLEKHM1+ MSCs. In summary, our data reveal an important role of BMM-derived sEVs for driving specifically BCR-ABL1+ B-ALL, possibly contributing to its worse prognosis compared with BCR-ABL1- B-ALL, and suggest that secretion of inflammatory cytokines by cancer cells in general may similarly modulate the tumor microenvironment.

Identifiants

pubmed: 36044386
pii: 486460
doi: 10.1182/bloodadvances.2022007528
pmc: PMC10111361
doi:

Substances chimiques

Syndecan-1 0
Syntenins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1190-1203

Informations de copyright

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Leukemia. 2018 Mar;32(3):575-587
pubmed: 28816238
Am J Hematol. 2019 Dec;94(12):1388-1395
pubmed: 31595534
J Clin Invest. 2013 Apr;123(4):1542-55
pubmed: 23454749
Nat Cell Biol. 2012 Jun 03;14(7):677-85
pubmed: 22660413
J Neuroinflammation. 2017 Apr 20;14(1):87
pubmed: 28427419
Cell Mol Life Sci. 2018 Jan;75(2):193-208
pubmed: 28733901
Onco Targets Ther. 2018 Aug 24;11:5151-5170
pubmed: 30210236
Nat Commun. 2020 Nov 26;11(1):5998
pubmed: 33243988
Mol Biol Cell. 2000 May;11(5):1829-43
pubmed: 10793155
Blood. 2016 Jul 21;128(3):453-6
pubmed: 27099150
J Extracell Vesicles. 2018 Aug 07;7(1):1505403
pubmed: 30108686
J Biol Chem. 2009 Aug 21;284(34):22865-77
pubmed: 19561089
Elife. 2019 Feb 05;8:
pubmed: 30720426
Stem Cells Dev. 2015 Jul 15;24(14):1635-47
pubmed: 25867197
J Clin Invest. 2007 Apr;117(4):919-30
pubmed: 17404618
Nat Immunol. 2007 May;8(5):463-70
pubmed: 17440452
J Biol Chem. 2015 Oct 23;290(43):26103-13
pubmed: 26350464
Cell Commun Signal. 2015 Apr 10;13:24
pubmed: 25889964
Nature. 2019 May;569(7755):222-228
pubmed: 30971824
Nat Protoc. 2012 Dec;7(12):2103-11
pubmed: 23154782
Front Oncol. 2014 Mar 25;4:54
pubmed: 24724051
Clin Cancer Res. 2013 Sep 1;19(17):4621-33
pubmed: 23873690
Mol Cell Biol. 1992 Jun;12(6):2662-72
pubmed: 1375324
Cell. 2011 Nov 11;147(4):728-41
pubmed: 22078875
Mol Biol Cell. 2010 Dec;21(23):4162-72
pubmed: 20943950
Leukemia. 2018 Nov;32(11):2326-2338
pubmed: 29740160
Leukemia. 2007 Aug;21(8):1723-32
pubmed: 17568820
Nature. 2014 Apr 24;508(7497):541-5
pubmed: 24670654
Methods Enzymol. 2020;645:55-78
pubmed: 33565978
Leukemia. 2020 Jul;34(7):1775-1786
pubmed: 31925317
Sci Transl Med. 2020 Sep 16;12(561):
pubmed: 32938796
J Cell Sci. 2018 Aug 3;131(15):
pubmed: 30076239
Leukemia. 2019 Apr;33(4):981-994
pubmed: 30185934
J Clin Invest. 2008 Feb;118(2):560-70
pubmed: 18219394
Nat Rev Cancer. 2020 May;20(5):285-298
pubmed: 32112045
Leuk Lymphoma. 2018 Nov;59(11):2535-2545
pubmed: 29431560
FASEB J. 2020 Aug;34(8):10191-10211
pubmed: 32557809
J Cell Commun Signal. 2019 Dec;13(4):443-450
pubmed: 31172413
Cell Death Dis. 2018 Mar 5;9(3):363
pubmed: 29507357
J Cell Sci. 2010 Nov 1;123(Pt 21):3796-807
pubmed: 20971705
J Exp Med. 2009 Mar 16;206(3):691-705
pubmed: 19255147
Cancer Res. 2007 Jan 15;67(2):585-92
pubmed: 17234767
Leukemia. 2020 Aug;34(8):2087-2101
pubmed: 32439895
Front Pharmacol. 2015 Oct 21;6:241
pubmed: 26539120
Blood. 2019 Jul 18;134(3):227-238
pubmed: 31003999
Haematologica. 2017 Sep;102(9):1594-1604
pubmed: 28596280
Oncotarget. 2015 May 10;6(13):11327-41
pubmed: 25857301
Cell. 2013 Jan 31;152(3):417-29
pubmed: 23374339
Leukemia. 2020 Jun;34(6):1540-1552
pubmed: 31919471
J Cell Biol. 2017 Apr 3;216(4):1051-1070
pubmed: 28325809
Lancet. 2013 Jun 1;381(9881):1943-55
pubmed: 23523389
Nat Med. 2006 Jun;12(6):657-64
pubmed: 16715089
Haematologica. 2015 Mar;100(3):295-9
pubmed: 25740105
Blood. 2015 Nov 19;126(21):2404-14
pubmed: 26297738
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Leuk Lymphoma. 1996 Mar;21(1-2):49-52
pubmed: 8907269
J Cell Sci. 2003 Apr 15;116(Pt 8):1409-16
pubmed: 12640026
Mol Cell. 2015 Jan 8;57(1):39-54
pubmed: 25498145
Cell Host Microbe. 2015 Jan 14;17(1):58-71
pubmed: 25500191
Cell Death Differ. 2009 Jan;16(1):70-8
pubmed: 19008921
Cell. 2006 Apr 7;125(1):113-26
pubmed: 16615894
Nat Med. 2013 Nov;19(11):1513-7
pubmed: 24162813
Proc Natl Acad Sci U S A. 2021 May 25;118(21):
pubmed: 34016751
Blood. 2021 Nov 11;138(19):1870-1884
pubmed: 34424946

Auteurs

Christina Karantanou (C)

Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.

Valentina R Minciacchi (VR)

Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.

Rahul Kumar (R)

Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.

Costanza Zanetti (C)

Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.

Jimena Bravo (J)

Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.

Raquel S Pereira (RS)

Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.

Georg Tascher (G)

Institute of Biochemistry II, Medical Faculty, Goethe University, Frankfurt am Main, Germany.

Tobias Tertel (T)

Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany.

Adriana Covarrubias-Pinto (A)

Institute of Biochemistry II, Medical Faculty, Goethe University, Frankfurt am Main, Germany.

Katrin Bankov (K)

Department of Pathology, Goethe University, Frankfurt am Main, Germany.

Lisa-Marie Pfeffermann (LM)

German Red Cross Blood Service Baden-Württemberg-Hessen, Institute Frankfurt, Frankfurt, Germany.

Halvard Bonig (H)

German Red Cross Blood Service Baden-Württemberg-Hessen, Institute Frankfurt, Frankfurt, Germany.
Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt, Germany.
Department of Medicine/Hematology, University of Washington, Seattle, WA.

Paola Divieti-Pajevic (P)

Goldman School of Dental Medicine, Boston University, Boston, MA.

David G McEwan (DG)

Cancer Research UK Beatson Institute, Glasgow, United Kingdom.

Bernd Giebel (B)

Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany.

Christian Münch (C)

Institute of Biochemistry II, Medical Faculty, Goethe University, Frankfurt am Main, Germany.

Ivan Dikic (I)

Institute of Biochemistry II, Medical Faculty, Goethe University, Frankfurt am Main, Germany.
Buchmann Institute for Molecular Life Sciences, Frankfurt am Main, Germany.

Daniela S Krause (DS)

Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.
Institute of Biochemistry II, Medical Faculty, Goethe University, Frankfurt am Main, Germany.
Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt, Germany.
Institute for General Pharmacology and Toxicology, Goethe University, Frankfurt am Main, Germany.
Frankfurt Cancer Institute, Frankfurt am Main, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH